Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from 10 to 11 directors with Anthony Pierce appointed as Class III director through 2028 annual meeting.
Amphastar Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 10 to 11 directors with Anthony Pierce appointed as Class III director through 2028 annual meeting
- Pierce deemed Nasdaq-independent, with no related-party transactions or selection arrangements disclosed
- Annual cash retainer $55,000, prorated for start date
- Initial equity grant valued at $300,000, split 50% restricted stock units and 50% stock options
- Equity grant vests after one year, subject to continued service
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amphastar Pharmaceuticals, Inc. 8-K filings
Get the next AMPH 8-K as it lands
Follow AMPH for push alerts, or ask the research agent what this filing means.